{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T17:41:00Z","timestamp":1788716460209,"version":"build-2803163510"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,1,1]]},"DOI":"10.1093\/jjco\/hyw146","type":"journal-article","created":{"date-parts":[[2016,10,8]],"date-time":"2016-10-08T01:30:13Z","timestamp":1475890213000},"page":"54-60","source":"Crossref","is-referenced-by-count":12,"title":["Safety, efficacy and pharmacokinetics of humanized anti-CD52 monoclonal antibody alemtuzumab in Japanese patients with relapsed or refractory B-cell chronic lymphocytic leukemia"],"prefix":"10.1093","volume":"47","author":[{"given":"Kenichi","family":"Ishizawa","sequence":"first","affiliation":[{"name":"Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Miyagi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Fukuhara","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Miyagi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiaki","family":"Nakaseko","sequence":"additional","affiliation":[{"name":"Department of Hematology, Chiba University Graduate School of Medicine, Chiba"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Chiba","sequence":"additional","affiliation":[{"name":"Department of Hematology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michinori","family":"Ogura","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya Daini Red Cross Hospital, Nagoya, Aichi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Sanofi K.K., Shinjuku-ku, Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Sunaga","sequence":"additional","affiliation":[{"name":"Sanofi K.K., Shinjuku-ku, Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensei","family":"Tobinai","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,1,25]]},"reference":[{"key":"key\n\t\t\t\t2018111409055596800_hyw146C1","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1056\/NEJM199510193331606","article-title":"Chronic lymphocytic leukemia","volume":"333","author":"Rozman","year":"1995","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2018111409055596800_hyw146C2","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.1994.12.9.1974","article-title":"Chronic lymphocytic leukemia: an updated review","volume":"12","author":"Faguet","year":"1994","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2018111409055596800_hyw146C3","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1034\/j.1600-0609.2001.5790514.x","article-title":"Chronic lymphocytic leukemia (CLL) is rare, but the proportion of T-CLL is high in Japan","volume":"67","author":"Tamura","year":"2001","journal-title":"Eur J Haematol"},{"key":"key\n\t\t\t\t2018111409055596800_hyw146C4","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1182\/blood.V50.6.1049.1049","article-title":"Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia","volume":"50","author":"Sawitsky","year":"1977","journal-title":"Blood"},{"key":"key\n\t\t\t\t2018111409055596800_hyw146C5","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1056\/NEJM200012143432402","article-title":"Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia","volume":"343","author":"Rai","year":"2000","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2018111409055596800_hyw146C6","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1200\/JCO.2001.19.8.2165","article-title":"Rituximab dose-escalation trial in chronic lymphocytic leukemia","volume":"19","author":"O'Brien","year":"2001","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2018111409055596800_hyw146C7","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(07)61125-8","article-title":"Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial","volume":"370","author":"Catovsky","year":"2007","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2018111409055596800_hyw146C8","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/JCO.2006.08.0762","article-title":"Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997","volume":"25","author":"Flinn","year":"2007","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2018111409055596800_hyw146C9","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2018111409055596800_hyw146C10","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","article-title":"Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study","volume":"99","author":"Keating","year":"2002","journal-title":"Blood"},{"key":"key\n\t\t\t\t2018111409055596800_hyw146C11","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1200\/JCO.2002.06.119","article-title":"Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine","volume":"20","author":"Rai","year":"2002","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2018111409055596800_hyw146C12","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1200\/JCO.2007.12.9098","article-title":"Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia","volume":"25","author":"Hillmen","year":"2007","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2018111409055596800_hyw146C13","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s12185-013-1393-x","article-title":"A phase I\/II study of ofatumumab (GSK1841157) in Japanese and Korean patients with relapsed or refractory B-cell chronic lymphocytic leukemia","volume":"98","author":"Ogawa","year":"2013","journal-title":"Int J Hematol"},{"key":"key\n\t\t\t\t2018111409055596800_hyw146C14"},{"key":"key\n\t\t\t\t2018111409055596800_hyw146C15","author":"ICH E6 (R1) Guideline for Good Clinical Practice"},{"key":"key\n\t\t\t\t2018111409055596800_hyw146C16","doi-asserted-by":"crossref","first-page":"633","DOI":"10.7326\/0003-4819-124-7-199604010-00003","article-title":"Natural history of opportunistic disease in an HIV-infected urban clinical cohort","volume":"124","author":"Moore","year":"1996","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t2018111409055596800_hyw146C17","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1182\/asheducation-2007.1.332","article-title":"Management of infectious complications in patients with chronic lymphocytic leukemia","author":"Morrison","year":"2007","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"key\n\t\t\t\t2018111409055596800_hyw146C18"},{"key":"key\n\t\t\t\t2018111409055596800_hyw146C19"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/47\/1\/54\/26567510\/hyw146.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T13:47:52Z","timestamp":1601128072000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/47\/1\/54\/2528036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,1]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,1,25]]},"published-print":{"date-parts":[[2017,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyw146","relation":{},"ISSN":["0368-2811","1465-3621"],"issn-type":[{"value":"0368-2811","type":"print"},{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,1]]},"published":{"date-parts":[[2017,1,1]]}}}